The Centers for Disease Control and Prevention Sept. 22 recommended the first maternal vaccine to protect newborns from severe illness from respiratory syncytial virus, the leading cause of hospitalization for U.S. infants. In a clinical study, the Pfizer vaccine (Abrysvo) reduced the risk of hospitalization by 57% in the first six months after birth. CDC recommends receiving one dose of the vaccine during weeks 32-36 of pregnancy.

“I encourage parents to talk to their doctors about how to protect their little ones against serious RSV illness, using either a vaccine given during pregnancy, or an RSV immunization given to your baby after birth,” said CDC Director Mandy Cohen, M.D.

The Food and Drug Administration approved the vaccine in August. It is currently available in some U.S. locations and should become more available in the coming weeks, CDC said.

Related News Articles

Headline
The AHA July 24 announced it is collaborating with health care technology leader Epic to help hospitals adopt tools that support the early detection and…
Headline
A Health Affairs study on the decline of obstetric services in rural and urban hospitals nationwide from 2010-2022 found that seven states had at least 25% of…
Headline
The latest video in the AHA’s series “Medicaid: Real Lives, Real Care” features Melissa Fannon-Wisner, DNP, nurse educator and nurse practitioner at Valley…
Headline
Kevin McEwan, DNP, R.N., chief nursing officer at Madison Memorial Hospital, shares how Medicaid provides vital behavioral health and maternal and child care…
Headline
The Alliance for Innovation on Maternal Health, with support from the Health Resources and Services Administration, will host a five-part learning series…
Blog
Even before the COVID pandemic, the mental health and wellness of our young people was failing. The pandemic exacerbated the crisis and made it difficult for…